Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States

References

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375.
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534–1539.
   PubMed Web of Science ®Google Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Therapy. 2009;26(9):847–857.
   PubMed Web of Science ®Google Scholar
• Plitt A, Ruff CT, Giugliano RP. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Hematol Oncol Clin North Am. 2016;30(5):1019–1034.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–982.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.
   PubMed Web of Science ®Google Scholar
• Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States. Int J Clin Pract. 2016;70(9):752–763.
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150(6):1302–1312.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017;33(10):1745–1754.
   PubMed Web of Science ®Google Scholar
• Li X, Keshishian A, Hamilton M, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One. 2018;13(1):e0191722.
   PubMed Web of Science ®Google Scholar
• Lin J, Trocio J, Gupta K, et al. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. J Med Econ. 2017;20(9):952–961.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Farmer C, Luo C, et al. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Cur Med Res Opin. 2018;34(3):487–498.
   PubMed Web of Science ®Google Scholar
• Hirschl M, Kundi M. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data. VASA. 2019;48(2):134–147.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tang J, Cui X, et al. Indirect comparison of novel oral anticoagulants among Asians with non-valvular atrial fibrillation in the real world setting: a network meta-analysis. BMC Cardiovasc Disord. 2019;19(1):182.
   PubMedGoogle Scholar
• Li G, Lip GYH, Holbrook A, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34(2):173–190.
   PubMed Web of Science ®Google Scholar
• Proietti M, Romanazzi I, Romiti GF, et al. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2018;49(1):98–106.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin. 2016;32(3):573–582. − 
   PubMed Web of Science ®Google Scholar
• Munir MB, Sharbaugh MS, Ahmad S, et al. Causes and predictors of 30-day readmissions in atrial fibrillation (from the Nationwide Readmissions Database). Am J Cardiol. 2017;120(3):399–403. − 
   PubMed Web of Science ®Google Scholar
• Freeman JV, Wang Y, Akar J, et al. National trends in atrial fibrillation hospitalization, readmission, and mortality for Medicare beneficiaries, 1999-2013. Circulation. 2017;135(13):1227–1239. − 
   PubMed Web of Science ®Google Scholar
• Bajaj NS, Kalra R, Patel N, et al. Comparison of approaches for stroke prophylaxis in patients with non-valvular atrial fibrillation: network meta-analyses of randomized controlled trials. PLoS One. 2016;11(10):e0163608.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Hill NR, Luo X, et al. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants. Int J Cardiol. 2018;269:174–181.
   PubMed Web of Science ®Google Scholar
• Strom JB, Kramer DB, Wang W, et al. Short-term rehospitalization across the spectrum of age and insurance types in the United States. PLoS One. 2017;12(7):e0180767.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Neuman WR, Lingohr-Smith M, et al. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. J Med Econ. 2017;20(12):1217–1223.
   PubMed Web of Science ®Google Scholar